Statin use after lobar intracerebral hemorrhage
StATins Use in intRacerebral hemorrhage patieNts (SATURN)
['FUNDING_U01'] · BETH ISRAEL DEACONESS MEDICAL CENTER · NIH-11325727
This trial compares continuing versus stopping statin medicines for people who had a lobar brain bleed and were taking statins.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BETH ISRAEL DEACONESS MEDICAL CENTER (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11325727 on ClinicalTrials.gov |
What this research studies
If you join, you will be randomly assigned to either keep taking your statin or stop it and then followed for 24 months. The trial is open-label (you and your doctors will know the assignment) but outcome assessors are blinded, and it enrolls patients at multiple medical centers. Researchers will track recurrent symptomatic intracerebral hemorrhage, major vascular events (like ischemic stroke or heart attack), as well as functional, cognitive, and quality-of-life outcomes. The study will also examine genetic markers (ApoE) and MRI signs such as microbleeds to see if some people face higher risk.
Who could benefit from this research
Good fit: Adults who suffered a lobar intracerebral hemorrhage and were taking statin medication at the time of the bleed are the main candidates for this trial.
Not a fit: People with non-lobar ICH, those who were not on statins at the time of their bleed, or those unable to change statin therapy are unlikely to benefit from participating.
Why it matters
Potential benefit: If successful, the results could clarify whether continuing or stopping statins after lobar ICH better protects patients from repeat brain bleeds while balancing prevention of heart and ischemic stroke events.
How similar studies have performed: There are no prior randomized trials on this specific question; observational data show statins reduce cardiovascular events but may modestly raise ICH risk in lobar cases, leaving the approach untested in randomized settings.
Where this research is happening
BOSTON, UNITED STATES
- BETH ISRAEL DEACONESS MEDICAL CENTER — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SELIM, MAGDY H — BETH ISRAEL DEACONESS MEDICAL CENTER
- Study coordinator: SELIM, MAGDY H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Arterial Obstructive Diseases, Arterial Obstructive Disorder, Arterial Occlusive Diseases, Arterial Occlusive Disorder